Self-Motivation
David Goggins
Former Navy Seal
Career Development
Bryan Cranston
Actor
Critical Thinking
Liv Boeree
International Poker Champion
Emotional Intelligence
Amaryllis Fox
Former CIA Clandestine Operative
Management
Chris Hadfield
Retired Canadian Astronaut & Author
Learn
from the world's big
thinkers
Start Learning

Court's Gene Patent Decision Not Based on Biology

The U.S. Supreme Court determined that biotechnology companies are not allowed to patent genes. The Court has not gone far enough.


Editor's Note: This article appeared on RealClearScience, and is paired with another that disagrees. Read that article here.

The U.S. Supreme Court, in a unanimous 9-0 decision, determined that biotechnology companies are not allowed to patent genes. This is a step in the right direction, but the Court has not gone far enough.

Myriad Genetics, the company at the center of the case, had patented the DNA sequences of the BRCA1 and BRCA2 genes and devised a test to determine if a woman possesses versions of the genes linked to breast cancer. However, by “owning” the gene sequences, they effectively created a monopoly, preventing other companies from creating their own tests.

The Court ruled against this, claiming that a product of nature – in this case, a gene sequence – is not eligible to be patented. But, a synthetic version of the gene, known as complementary DNA (cDNA), is eligible. This sounds like a fair-minded compromise, but it could yet still prove greatly problematic for the scientific community.

Scattered within our genes are bits of rather mysterious DNA sequences called introns. Their purpose is largely unknown. To express a gene, a cell first converts the DNA sequence into messenger RNA (mRNA), but it snips out all the pesky introns. The pieces left over to make the RNA message provide the instructions necessary to synthesize proteins. If a team of scientists creates a DNA version of this protein-encoding mRNA, it is called cDNA and is eligible for patenting.

The trouble is that cDNA – while considered “synthetic” – is essentially nothing more than a simplified version of the same information already contained within the gene. The Court claimed “cDNA is patent eligible because it is not naturally occurring.” But this is scientifically dubious. True, cDNA itself isn’t found in nature, but the information is: It comes in the form of mRNA, which is abundant within a cell. In other words, there isn’t any novel, non-natural information in the cDNA.

Think of this analogy: A company that mines an ore, processes it, and extracts the pure metal is not allowed to patent the metal. Why? Because the metal is still a product of nature. “Simplifying” the ore by extracting the metal doesn’t make the metal patent eligible.

Even more troublesome for biologists is the fact that creating cDNA to study genes is extremely common in genetics laboratories. Therefore, if cDNA is patent eligible, it would suggest that studying the original gene is still largely off limits to those who don’t hold the patent. If that’s the case, then the Court’s decision hasn’t changed the status quo all that much.

What should be eligible for a patent? Any substantial change that produces a gene sequence that is not known to occur in nature should be patent eligible.

For example, non-natural mutations can be introduced into a gene sequence in order to study function; this often takes the form of DNA deletions and insertions, or in some cases, fusions with other genes. Other changes involve tweaking how the gene is expressed. Such manipulations should be patent eligible if a company decides to pursue that.

As a book author, I certainly recognize the necessity and value in protecting intellectual property. Without patents, technology simply would not progress.

Striking the proper balance between promoting innovation and allowing public access to scientific information is a delicate balancing act. Unfortunately, the Court has failed in this endeavor.

Alex B. Berezow is the editor of RealClearScience and co-author of Science Left Behind. He holds a PhD in microbiology.

Live on Tuesday | Personal finance in the COVID-19 era

Sallie Krawcheck and Bob Kulhan will be talking money, jobs, and how the pandemic will disproportionally affect women's finances.

4 ways to promote neurogenesis in your brain

How can we promote the creation of new neurons - and why is it so important?

We can promote the development of new neurons well into adulthood - and here's why we should.

Image by vrx on Shutterstock
Mind & Brain
  • Neurogenesis, the birth of neurons from stem cells, happens mostly before we are born - as we are formed in the womb, we are generating most of what we need after birth.
  • After birth, neurogenesis is still possible in two parts of the brain: the olfactory bulb (which is responsible for our sense of smell) and the hippocampus (which is responsible for memory, spatial navigation, and emotional processing).
  • Research from the 1960s proves creating new neurons as adults is possible, and modern-day research explains how (and why) we should promote new neuron growth.
Keep reading Show less

Why is everyone so selfish? Science explains

The coronavirus pandemic has brought out the perception of selfishness among many.

Credit: Adobe Stock, Olivier Le Moal.
Personal Growth
  • Selfish behavior has been analyzed by philosophers and psychologists for centuries.
  • New research shows people may be wired for altruistic behavior and get more benefits from it.
  • Crisis times tend to increase self-centered acts.
Keep reading Show less

How Hemingway felt about fatherhood

Parenting could be a distraction from what mattered most to him: his writing.

Ernest Hemingway Holding His Son 1927 (Wikimedia Commons)
Culture & Religion

Ernest Hemingway was affectionately called “Papa," but what kind of dad was he?

Keep reading Show less
Videos

The biology of aliens: How much do we know?

Hollywood has created an idea of aliens that doesn't match the science.

Scroll down to load more…
Quantcast